Drug Profile
Research programme: phosphatidylinositol 3-kinase inhibitors - Pathway Therapeutics
Alternative Names: Irrerversible PI3K; PI3K delta; PIK-75Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pathway Therapeutics
- Class
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Haematological malignancies; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in New Zealand
- 16 Jul 2016 No recent reports of development identified for research development in Haematological-malignancies in New Zealand
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in New Zealand